KDR and neoplasm: In the EMT6-LM2 tumor model, moderate tumor growth inhibition was observed with anti-PD-L1 and anti-VEGFR-2 antibody monotherapies (anti-PD-L1, complete response [CR] = 1; anti-VEGFR-2, CR = 2) (Fig 2E and 2G).